-
Je něco špatně v tomto záznamu ?
Mucosal healing is not associated with better outcome during 7 years of follow-up in pediatric patients with Crohn's disease
J. Melek, M. Štanclová, P. Dědek, R. Štichhauer, J. Koudelka, T. Douda, I. Tachecí, L. Douda, T. Vaňásek, J. Bureš
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články
- MeSH
- časové faktory MeSH
- centra terciární péče MeSH
- Crohnova nemoc * terapie MeSH
- dítě MeSH
- hojení ran MeSH
- hospitalizace * statistika a číselné údaje MeSH
- infliximab terapeutické užití MeSH
- lidé MeSH
- mladiství MeSH
- následné studie MeSH
- retrospektivní studie MeSH
- střevní sliznice * patologie MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Mucosal healing (MH) has become a perspective treatment target in patients with Crohn's disease (CD). Data about the impact of MH on long-term outcome in pediatric patients are still scarce. METHODS: Seventy-six pediatric patients with CD were evaluated retrospectively (2000-2015) in a tertiary care center. Based on MH achievement, they were divided into two groups (MH, N.=17; and No MH, N.=59). The primary endpoint was to assess the association of MH and the need for CD-related hospitalizations or surgery in pediatric patients with CD. RESULTS: The number of hospitalized patients was 24% in the MH group and 42% in the No MH group (P=0.26). The total number of CD-related hospitalizations was not significant between the MH group and the No MH group (5 vs. 41, P=0.15). The time to the first hospitalization was 24 months in MH and 21 months in No MH (P>0.99). About 24% of the patients in the MH group and 39% patients in the No MH group underwent CD-related operation (P=0.39). Time to the first operation was 43 months for MH and 19 months for the No MH group (P=0.13). The follow-up period was 91 months in the MH group and 80 months in the No MH group (P=0.74). The use of infliximab was positively associated with MH (P=0.002). CONCLUSIONS: MH was not associated with fewer CD-related hospitalizations or operations in pediatric patients with CD during seven years of follow-up.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013830
- 003
- CZ-PrNML
- 005
- 20240905134410.0
- 007
- ta
- 008
- 240725s2024 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.23736/S2724-5276.21.06099-0 $2 doi
- 035 __
- $a (PubMed)33845563
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Melek, Jan $u Department of Pediatrics, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic - jan.melek1@gmail.com
- 245 10
- $a Mucosal healing is not associated with better outcome during 7 years of follow-up in pediatric patients with Crohn's disease / $c J. Melek, M. Štanclová, P. Dědek, R. Štichhauer, J. Koudelka, T. Douda, I. Tachecí, L. Douda, T. Vaňásek, J. Bureš
- 520 9_
- $a BACKGROUND: Mucosal healing (MH) has become a perspective treatment target in patients with Crohn's disease (CD). Data about the impact of MH on long-term outcome in pediatric patients are still scarce. METHODS: Seventy-six pediatric patients with CD were evaluated retrospectively (2000-2015) in a tertiary care center. Based on MH achievement, they were divided into two groups (MH, N.=17; and No MH, N.=59). The primary endpoint was to assess the association of MH and the need for CD-related hospitalizations or surgery in pediatric patients with CD. RESULTS: The number of hospitalized patients was 24% in the MH group and 42% in the No MH group (P=0.26). The total number of CD-related hospitalizations was not significant between the MH group and the No MH group (5 vs. 41, P=0.15). The time to the first hospitalization was 24 months in MH and 21 months in No MH (P>0.99). About 24% of the patients in the MH group and 39% patients in the No MH group underwent CD-related operation (P=0.39). Time to the first operation was 43 months for MH and 19 months for the No MH group (P=0.13). The follow-up period was 91 months in the MH group and 80 months in the No MH group (P=0.74). The use of infliximab was positively associated with MH (P=0.002). CONCLUSIONS: MH was not associated with fewer CD-related hospitalizations or operations in pediatric patients with CD during seven years of follow-up.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Crohnova nemoc $x terapie $7 D003424
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a hospitalizace $x statistika a číselné údaje $7 D006760
- 650 12
- $a střevní sliznice $x patologie $7 D007413
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a hojení ran $7 D014945
- 650 _2
- $a centra terciární péče $7 D062606
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a infliximab $x terapeutické užití $7 D000069285
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Štanclová, Markéta $u Department of Pediatrics, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Dědek, Petr $u Department of Pediatrics, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Štichhauer, Radek $u Department of Pediatric Surgery and Traumatology, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Koudelka, Jaroslav $u Department of Pediatric Surgery and Traumatology, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Douda, Tomáš $u Second Department of Internal Medicine and Gastroenterology, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Tachecí, Ilja $u Second Department of Internal Medicine and Gastroenterology, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Douda, Ladislav $u Second Department of Internal Medicine and Gastroenterology, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Vaňásek, Tomáš $u Hepatogastroenterologie HK, s.r.o, Hradec Králové, Czech Republic
- 700 1_
- $a Bureš, Jan $u Second Department of Internal Medicine and Gastroenterology, Faculty of Medicine in Hradec Králové, University Hospital of Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 773 0_
- $w MED00209466 $t Minerva pediatrics $x 2724-5780 $g Roč. 76, č. 3 (2024), s. 381-387
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33845563 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134404 $b ABA008
- 999 __
- $a ok $b bmc $g 2143569 $s 1225696
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 76 $c 3 $d 381-387 $e 20210412 $i 2724-5780 $m Minerva pediatrics $n Minerva Pediatr (Torino) $x MED00209466
- LZP __
- $a Pubmed-20240725
